Skye Bioscience, Inc. Common Stock (SKYE) is a publicly traded Healthcare sector company. As of May 20, 2026, SKYE trades at $0.74 with a market cap of $27.33M and a P/E ratio of -0.52. SKYE moved +0.00% today. Year to date, SKYE is -17.42%; over the trailing twelve months it is -66.27%. Its 52-week range spans $0.57 to $5.96. Analyst consensus is buy with an average price target of $9.50. Rallies surfaces SKYE's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Skye Bioscience Advances to 600mg Nimacimab Cohort After Safe 400mg Dosing: Skye Bioscience’s safety committee approved enrollment in Cohort 2 of its CBeyond Part C Expansion Study after four participants completed four 400 mg IV nimacimab doses with no serious or special-interest adverse events. Cohort 2 will test 600 mg IV weekly in six active and two placebo participants over 15 weeks.
| Metric | Value |
|---|---|
| Price | $0.74 |
| Market Cap | $27.33M |
| P/E Ratio | -0.52 |
| EPS | $-1.41 |
| Dividend Yield | 0.00% |
| 52-Week High | $5.96 |
| 52-Week Low | $0.57 |
| Volume | 48.16K |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-55.92M |
| Gross Margin | 0.00% |
6 analysts cover SKYE: 0 strong buy, 4 buy, 2 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $9.50.